Literature DB >> 12604974

Body composition and components of energy expenditure in children with end-stage liver disease.

Ristan Greer1, Megan Lehnert, Peter Lewindon, Geoffrey J Cleghorn, Ross W Shepherd.   

Abstract

BACKGROUND: Better understanding of body composition and energy metabolism in pediatric liver disease may provide a scientific basis for improved medical therapy aimed at achieving optimal nutrition, slowing progression to end-stage liver disease (ESLD), and improving the outcome of liver transplantation.
METHODS: Twenty-one children less than 2 years of age with ESLD awaiting liver transplantation and 15 healthy, aged-matched controls had body compartment analysis using a four compartment model (body cell mass, fat mass, extracellular water, and extracellular solids). Subjects also had measurements of resting energy expenditure (REE) and respiratory quotient (RQ) by indirect calorimetry. Nine patients and 15 control subjects also had measurements of total energy expenditure (TEE) using doubly labelled water.
RESULTS: Mean weights and heights were similar in the two groups. Compared with control subjects, children with ESLD had higher relative mean body cell mass (33 +/- 2% vs 29 +/- 1% of body weight, P < 0.05), but had similar fat mass, extracellular water, and extracellular solid compartments (18% vs 20%, 41% vs 38%, and 7% vs 13% of body weight respectively). Compared with control subjects, children with ESLD had 27% higher mean REE/body weight (0.285 +/- 0.013 vs 0.218. +/- 0.013 mJ/kg/24h, P < 0.001), 16% higher REE/unit cell mass (P < 0.05); and lower mean RQ (P < 0.05). Mean TEE of patients was 4.70 +/- 0.49 mJ/24h vs 3.19 +/- 0.76 in controls, (P < 0.01).
CONCLUSIONS: In children, ESLD is a hypermetabolic state adversely affecting the relationship between metabolic and nonmetabolic body compartments. There is increased metabolic activity within the body cell mass with excess lipid oxidation during fasting and at rest. These findings have implications for the design of appropriate nutritional therapy.

Entities:  

Mesh:

Year:  2003        PMID: 12604974     DOI: 10.1097/00005176-200303000-00010

Source DB:  PubMed          Journal:  J Pediatr Gastroenterol Nutr        ISSN: 0277-2116            Impact factor:   2.839


  9 in total

1.  Parenteral nutrition supplementation in biliary atresia patients listed for liver transplantation.

Authors:  Jillian S Sullivan; Shikha S Sundaram; Zhaoxing Pan; Ronald J Sokol
Journal:  Liver Transpl       Date:  2012-01       Impact factor: 5.799

2.  Variability of resting energy expenditure in infants and young children with intestinal failure-associated liver disease.

Authors:  Debora Duro; Paul D Mitchell; Nilesh M Mehta; Lori J Bechard; Yong-Ming Yu; Tom Jaksic; Christopher Duggan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2014-05       Impact factor: 2.839

3.  Growth failure and outcomes in infants with biliary atresia: a report from the Biliary Atresia Research Consortium.

Authors:  Patricia A DeRusso; Wen Ye; Ross Shepherd; Barbara A Haber; Benjamin L Shneider; Peter F Whitington; Kathleen B Schwarz; Jorge A Bezerra; Philip Rosenthal; Saul Karpen; Robert H Squires; John C Magee; Patricia R Robuck; Ronald J Sokol
Journal:  Hepatology       Date:  2007-11       Impact factor: 17.425

Review 4.  Beyond the Pediatric end-stage liver disease system: solutions for infants with biliary atresia requiring liver transplant.

Authors:  Mary Elizabeth M Tessier; Sanjiv Harpavat; Ross W Shepherd; Girish S Hiremath; Mary L Brandt; Amy Fisher; John A Goss
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

Review 5.  Screening and outcomes in biliary atresia: summary of a National Institutes of Health workshop.

Authors:  Ronald J Sokol; Ross W Shepherd; Riccardo Superina; Jorge A Bezerra; Patricia Robuck; Jay H Hoofnagle
Journal:  Hepatology       Date:  2007-08       Impact factor: 17.425

6.  Serum proinflammatory cytokines and nutritional status in pediatric chronic liver disease.

Authors:  Daniele Santetti; Maria Inês de Albuquerque Wilasco; Cristina Toscani Leal Dornelles; Isabel Cristina Ribas Werlang; Fernanda Urruth Fontella; Carlos Oscar Kieling; Jorge Luiz Dos Santos; Sandra Maria Gonçalves Vieira; Helena Ayako Sueno Goldani
Journal:  World J Gastroenterol       Date:  2015-08-07       Impact factor: 5.742

Review 7.  Advances in management of end stage liver disease in children.

Authors:  Aradhana Aneja; Elizabeth Scott; Rohit Kohli
Journal:  Med J Armed Forces India       Date:  2021-03-25

Review 8.  Nutritional Needs and Support for Children with Chronic Liver Disease.

Authors:  Christine H Yang; Brandon J Perumpail; Eric R Yoo; Aijaz Ahmed; John A Kerner
Journal:  Nutrients       Date:  2017-10-16       Impact factor: 5.717

9.  Feeding practices in 6-24-month-old children with chronic cholestatic liver diseases: a mixed-method study.

Authors:  Xiao Chen; Jianshe Wang; Yi Lu; Xinbao Xie; Ying Gu; Jos M Latour; Yuxia Zhang
Journal:  BMC Pediatr       Date:  2020-08-24       Impact factor: 2.125

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.